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ABSTRACT The U.S. National Institutes of Health
(NIH) are facing significant budgetary challenges as a
result of the current economic climate. The recent
sunset of investigator-initiated R01-type research grants
after one revised submission, coupled with the present
lack of an NIH retooling funding mechanism for such
grant applicants, creates a concerning risk that talented
and well-trained investigators may be forced to give up
their research careers. Existing NIH retooling mecha-
nisms include the R55 Shannon Award, which was
established in 1991 and was essentially replaced in 2005
by the R56 award. There is an urgent need to either
significantly expand the R55/R56 mechanisms and
definition of NIH grant bridging/retooling support for
unfunded meritorious proposals or introduce a new
mechanism that provides specific support to investiga-
tors with competitive but unfunded R01 revised grants.
An expanded retooling funding mechanism deserves
implementation during continuing assessment of whether
allowance of only one revision of research proposals
has achieved its initial intended goals.—Omary, M. B.,
Offhaus, H., Kunkel, S. L. Two strikes: limited NIH
R55 and R56 retooling funds and abolishment of the
A2 grant mechanism. FASEB J. 25, 4108 – 4110 (2011).
www.fasebj.org
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There are current major financial concerns regard-
ing the effect of national budget constraints on re-
search funding by the U.S. National Institutes of Health
(NIH) and other federal science-related spending. The
significance of these financial constraints is readily
observed at the level of NIH investigator-initiated R01
extramural grants, for which success funding levels
have steadily decreased to single digits across several
NIH Institutes (1). Furthermore, concerns regarding
the markedly declining success in funding have been
compounded by the elimination of the A2 mechanism
of grant reapplication (i.e., second revision of an initial
R01 grant application; ref. 2), and the present lack of
any well-defined NIH sponsored bridging or retooling
mechanisms should the A1 first-revision application not
be funded. Added to this is the recent NIH budget
reduction from $31.2 billion in 2010 to $30.9 billion in
2011 and the projected further cuts in 2012 (3). The
spending power of this budget has already been ham-
pered by an average annual increase of 1.5% since
2005 that is far below the annual inflation rate. Discon-
tinuation of the A2 mechanism as of 2009 means that
grants not funded after an unsuccessful first A1 revision
will no longer be considered and would have to be
submitted as a new proposal that is substantially differ-
ent from the last A1 version (2). This creates a major
problem for those unfunded investigators, particularly
those whose research program depends on a single
R01.
HISTORICAL PERSPECTIVE AND OVERVIEW OF
THE R55 AND R56 MECHANISMS
In prior years, the NIH used a bridging mechanism,
termed the R55 Shannon Award, named after former
NIH Director James A. Shannon (also called Director’s
Awards, a category of awards first established in 1991 by
then NIH Director Bernadine Healy; ref. 4). R55
awards provide limited funds (historically $100,000
for 1 yr; Table 1 and ref. 5) to applicants of meritorious
grants that did not meet the payline. The R55 mecha-
nism has been used by NIH institutes in a very limited
fashion since 2006 (Table 1). Another important re-
tooling funding mechanism is the R56, which provides
critical support for investigators who are between the
initial grant submission (A0) and A1 stages. R56 sup-
port has increased since its inception in 2005, except
for a decline during 2009 (Table 1) that is arguably
related to funding strategies introduced under the
American Recovery and Reinvestment Act (ARRA) of
2009 to target funds for meritorious projects not
funded under the base appropriation. Depending on
the institute, some preference is given to new investi-
gators for the awarding of R56 grants, as is the case for
the National Institute of Diabetes and Digestive and
Kidney Diseases (6). A 2008 NIH announcement that
described the NIH Director’s Bridge Awards (NDBAs)
stated:
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A pending, competing renewal research project
grant (R01) application (original) or a resubmis-
sion application (A1, A2), which just misses the
nominal funding payline for the IC to which it is
primarily assigned may be nominated for the
NDBA by the administering NIH Institute, pro-
vided the PI has less than $400,000 in other
support (total costs) from all sources to fund
her/his research. Note that only the most merito-
rious A2 applications will be considered for the
NDBA. Applicants may not apply for an R56 grant
and applicants may not self nominate for the
NDBA.
Total costs approved by the Institute or Center
for the first year of the project up to $500,000 will
be provided using a one year R56 grant. (7)
In 1991, 316 R55 awards were given, distributed as
follows: 196 after submissions of A0 initial grants, 91
after A1 grants, 23 after A2 grants, and 6 after A3 grants
(8) (this was during the period when multiple resub-
missions were allowed!). The allocation of $30 million
for the R55 program in 1991 represented 0.36% of the
$8.28 billion budget at that time (9). Notably, an
analysis of the 316 funded R55 grants showed that 142
R55 awardees were able to sustain funding, based on
retaining the same project number for at least 3 yr (8).
This implies a success rate of R55-supported subse-
quent funding of 44.9%, which is far better than the
reported 1991 success rates of 28.6% for R01 equiva-
lents (R01, R23, R29, and R37; ref. 10), and indicates
that such bridging support did indeed lead to high
subsequent success.
To quote Dr. Healy’s illuminating comment to a
congressional panel: “We do not expect 1991 by any
means to be a year in which we fund more than 25 or
26 percent of the applications. That is a skimpy success
rate and we hope the Shannon awards will help even a
little in sustaining as many as 300 to 400 scientists” (11).
Now, 20 yr later, times have changed and produced
payline percentiles (in contrast to the typically higher
“success rates”; ref. 12) that are in the range of 8–15%,
with typically higher funding percentiles for new inves-
tigators (1). These percentiles are far lower now than
those just a few years ago [e.g., for National Institute of
Allergy and Infectious Diseases, the percentiles are 10%
(2011), 11% (2010), 14% (2006), and 20–22% (1999–
2004); ref. 13].
A PROPOSED NEW RETOOLING MODEL
If the R55/R56 mechanism continues to support mer-
itorious applications between the A0 to A1 stage at the
same proportionate level of the NIH 1991 budget, then
allocation of nearly $110 million would be needed,
which is in line with the allocations made during
2009–2010 (which excludes ARRA funds), and we hope
that this will continue. Our proposal deals specifically
with applications that are close to but do not meet the
payline after an A1 application. This is a watershed area
that deserves attention, particularly for investigators
who have no other R-equivalent funding or who have
limited funding such as an R21.
With a very low funding percentile (even assuming
success at the 15th percentile), the difference in fund-
ing merit between those grants falling in the 12th–15th
and 15th–18th percentile is highly subjective. In addi-
tion, investigators with a borderline unfunded A1 ap-
plication score can no longer revise their application
but, instead, need to start afresh while lacking any
support except for what may be provided by the inves-
tigator’s institution. With a fixed pot, the obvious
question is where the bridge funds will come from. One
potential source is the Director’s Discretionary Fund
TABLE 1. Initial and total and R55 and R56 NIH awards 2001–2010
Year
Initial awards Total awards
R55 R56 R55 R56
Awards Dollars (millions) Awards Dollars (millions) Awards Dollars (millions) Awards Dollars (millions)
2001 14 1.4 14 1.4
2002 22 2.2 22 2.2
2003 14 1.4 14 1.4
2004 11 1.1 11 1.1
2005 8 0.8 47 11.7 9 0.9 107 26.1
2006 3 0.3 54 15.7 4 0.4 113 28.7
2007 5 0.5 66 19.9 5 0.5 361 123.1
2008 2 0.2 87 29.3 2 0.2 419 137.8
2009 2 0.2 43 17.5 2 0.2 308 116.9
2010 0 0 138 55.8 0 0 234 91.6
Data were obtained from ref. 5. Numbers do not include ARRA numbers (see ref. 8 to obtain the latter). The NIH-stated goal of the R55
is to “provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available
data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research
capabilities and lend additional weight to their already meritorious applications” (17). The NIH-stated goal of the R56 is to “provide limited
interim research support based on the merit of a pending R01 application while applicant gathers additional data to revise a new or competing
renewal application. This grant will underwrite highly meritorious applications that if given the opportunity to revise their application could
meet IC recommended standards and would be missed opportunities if not funded” (17). The discrepancy between the number of initial and
total awards is probably related to the duration of some of the awards (1 or 2 yr) and whether some have no-cost extensions.
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(DDF), which had provided the R55 Shannon and the
R56 awards. In federal fiscal year 2010, the DDF was
$634 million and was used, in part, for the Director
Pioneer Awards and other initiatives. Based on an
assumption of the historical allocation of $100,000 per
award (which can be increased to $150,000), we would
project that an allocation of $50 million (7.9% of the
2010 DDF) would bridge 300–500 investigators on an
annual basis. It may be reasonable to consider structur-
ing the award similar to a career development award
with limited indirect rates, coupled with institute ceil-
ings on salary recovery, to maximize both the allocation
and the number of investigators that could be funded
from the designated pool. Because of the nature of
bridging support and the opportunity for protected
time to retool the necessary methods or develop addi-
tional data sets, institutions would probably be willing
partners with NIH under the program.
If the NIH spends the proposed $50 million on
bridging support, this would represent only 3.4% of the
$1.45 billion that was spent by the NIH in 2010 to fund
resubmitted new R01s and resubmitted continuation
R01s (excluding ARRA-funded awards) (14). Further-
more, using 2010 NIH grant data, the addition of 300
bridging awards is estimated to add 8.1% additional
investigators to the 3712 investigators who were
awarded R01 grants during 2010 and who do not hold
any additional R01 grants (14).
With regard to the sunset of the A2, benefits such as
a rise in the number of funded applications after initial
submission (A0) and an increase in funding of new
investigators are invoked as some of the benefits of its
elimination (15). However, these benefits are yet to be
proven, as the upswing in these figures started in 2009
and may be related to infusion by the ARRA or to the
abolishment of the A2 mechanism, which by definition
implies an increase in the number of funded A0 and A1
grants. It may still be too early to make concrete
conclusions regarding the true effect of the sunset of
the A2 mechanism. However, with a declining compet-
itive funding percentile, it is hard to discount the effect
it immediately has on investigators at all levels, whether
they are relatively junior investigators who are attempt-
ing to renew a first NIH R01 grant or more established
investigators (16). Clearly, many investigators who are
affected are those whom the system has invested in for
years and now may be forced to abandon research or
consider relocating to other countries willing to pro-
vide them with research support. Other unintended
consequences are that a harsh research funding envi-
ronment is a disincentive to young talent to join the
research workforce (to maintain the pipeline) and an
incentive for talented established investigators (who
help maintain the pipe) to consider other career
options (e.g., a physician-scientist leaving research for a
pure clinical practice).
We have reached a critical stage in the need for
identifying bridging and retooling opportunities for
investigators. The national push for scientific advance-
ment, in tension with stagnant appropriations, low
competitive success margins, and the requirement to
substantially overhaul scientific direction in unsuccess-
ful projects, has the potential to create cracks in our
research workforce. A partnership between NIH and
investigators’ home institutions will be an important
step forward to navigate this challenge. These factors
lead to the conclusion that there is an urgent need to
significantly expand the R55/R56 mechanism of bridg-
ing or introduce a new funding mechanism for retool-
ing, while continuing to assess any overriding benefit
from the elimination of A2 proposals. If implementa-
tion of the proposed retooling program herein is
deemed by the NIH leadership to be acceptable, then
specific criteria and guidelines can be promptly estab-
lished with the aid of NIH intramural and extramural
input.
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